EUVIMED · CrossrefZeitschrift
Immunotherapy Advances
ISSN 2732-4303 · Oxford University Press (OUP)
Neueste Artikel
The UK vaccine innovation pathway
Targeted 19F MRI for molecular imaging of the immune response and its theranostics
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure
Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials
Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma
Comparing DC subsets in solid tumors: what about DC3s?
Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
Harnessing natural killer cell effector function against cancer
Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives
Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
Efficacy of smallpox vaccines against Mpox infections in humans
NLRP3 inflammasome activation in sensory neurons promotes chronic inflammatory and osteoarthritis pain
Efficacy of PD-1 checkpoint inhibitor therapy in melanoma and beyond: are peripheral T cell phenotypes the key?
Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer
Adrenergic signaling regulation of macrophage function: do we understand it yet?
Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?
Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy
Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors
Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
CAR-T cells leave the comfort zone: current and future applications beyond cancer
Behind the scenes with basophils: an emerging therapeutic target
α2-3 Sialic acid binding and uptake by human monocyte-derived dendritic cells alters metabolism and cytokine release and initiates tolerizing T cell programming
Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers
100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes
Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells
The MARVEL trial: a phase 2b randomised placebo-controlled trial of oral MitoQ in moderate ulcerative colitis
EUVIMED